论文部分内容阅读
目的:评估干扰素加胸腺肽治疗慢性乙型肝炎的疗效。方法:60例慢性乙型肝炎患者随机分成2组。治疗组:干扰素α-2b300万单位,肌注,每日1次,肌注1月后再改为隔日肌注,用2个月;胸腺肽100mg加入10％的葡萄糖静滴,每日1次,共用3个月。对照组:只用干扰素,剂量、疗程同治疗组。结果:治疗组中ALT复常率为86.7％,HBsAg阴转率为13.3％,HBeAg阴转率66.7％,HBV DNA阴转率为70.0％;而对照组中ALT复常率为83.3％,HBsAg阴转率为10.0％,HBeAg阴转率40.0％,HBV DNA阴转率为50.0％。随访半年,治疗组HBeAg、HBVDNA19例阴转,而对照组仅9例阴转。结论:干扰素加胸腺肽联合治疗慢性乙型肝炎具有协同作用,可以提高远期疗效。
OBJECTIVE: To evaluate the efficacy of interferon plus thymosin in the treatment of chronic hepatitis B. Methods: Sixty patients with chronic hepatitis B were randomly divided into two groups. The treatment group: Interferon α-2b300 million units, intramuscular injection, once a day, intramuscular injection of 1 month and then changed to intramuscular injection, with 2 months; Thymosin 100mg 10% glucose intravenous infusion once daily , Sharing 3 months. Control group: only interferon, dose, treatment with the treatment group. Results: The recovery rate of ALT was 86.7%, the negative conversion rate of HBsAg was 13.3%, the negative conversion rate of HBeAg was 66.7% and the negative conversion rate of HBV DNA was 70.0% in the treatment group, while that of the control group was 83.3% The negative conversion rate was 10.0%, the negative conversion rate of HBeAg was 40.0%, and the negative conversion rate of HBV DNA was 50.0%. Follow-up six months, the treatment group HBeAg, HBVDNA19 cases overcast, while the control group, only 9 cases of negative. Conclusion: Interferon plus thymosin combined treatment of chronic hepatitis B has a synergistic effect, can improve long-term efficacy.